Free Trial
NASDAQ:SNGX

Soligenix (SNGX) Stock Price, News & Analysis

Soligenix logo
$3.67
-0.06 (-1.61%)
(As of 05:46 PM ET)

About Soligenix Stock (NASDAQ:SNGX)

Key Stats

Today's Range
$3.60
$3.82
50-Day Range
$3.27
$4.87
52-Week Range
$1.83
$32.00
Volume
41,181 shs
Average Volume
881,896 shs
Market Capitalization
$8.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Soligenix Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
9th Percentile Overall Score

SNGX MarketRank™: 

Soligenix scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Soligenix are expected to grow in the coming year, from ($5.10) to ($2.93) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Soligenix is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Soligenix is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Soligenix has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Soligenix's valuation and earnings.
  • Percentage of Shares Shorted

    5.89% of the float of Soligenix has been sold short.
  • Short Interest Ratio / Days to Cover

    Soligenix has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Soligenix has recently increased by 5.09%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Soligenix does not currently pay a dividend.

  • Dividend Growth

    Soligenix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.89% of the float of Soligenix has been sold short.
  • Short Interest Ratio / Days to Cover

    Soligenix has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Soligenix has recently increased by 5.09%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Soligenix has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Soligenix this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for SNGX on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 2 people have added Soligenix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Soligenix insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.80% of the stock of Soligenix is held by insiders.

  • Percentage Held by Institutions

    Only 3.60% of the stock of Soligenix is held by institutions.

  • Read more about Soligenix's insider trading history.
Receive SNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Soligenix and its competitors with MarketBeat's FREE daily newsletter.

SNGX Stock News Headlines

Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
Soligenix granted Hong Kong patent for production of synthetic hypericin
See More Headlines

SNGX Stock Analysis - Frequently Asked Questions

Soligenix's stock was trading at $12.1152 at the beginning of 2024. Since then, SNGX shares have decreased by 69.7% and is now trading at $3.67.
View the best growth stocks for 2024 here
.

Soligenix, Inc. (NASDAQ:SNGX) announced its earnings results on Friday, August, 9th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, beating analysts' consensus estimates of ($2.11) by $0.80. Soligenix had a negative trailing twelve-month return on equity of 256.12% and a negative net margin of 1,473.38%.

Soligenix shares reverse split before market open on Thursday, June 6th 2024. The 1-16 reverse split was announced on Thursday, June 6th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 6th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Soligenix's top institutional shareholders include Stephens Inc. AR (4.69%). Insiders that own company stock include Christopher J Schaber, Richard Straube and Jonathan L Guarino.
View institutional ownership trends
.

Shares of SNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Soligenix investors own include Tonix Pharmaceuticals (TNXP), Trevena (TRVN), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), T2 Biosystems (TTOO), iBio (IBIO) and Dynavax Technologies (DVAX).

Company Calendar

Last Earnings
8/09/2024
Today
10/31/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNGX
Employees
20
Year Founded
1987

Profitability

Net Income
$-6,140,000.00
Net Margins
-1,473.38%
Pretax Margin
-1,603.77%

Debt

Sales & Book Value

Annual Sales
$840,000.00
Book Value
$3.83 per share

Miscellaneous

Free Float
2,216,000
Market Cap
$3.72 million
Optionable
Not Optionable
Beta
1.84

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:SNGX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners